As always, a paraphrase. Bottom line is that a straight line ramp of sales is anticipated for another 2-3 quarters (Management says so too). In a sample of hematologic oncologists, there wasn't a whole lot of enthusiasm for the apparent life extension and there certainly wasn't any enthusiasm for giving Jakafi to patients with mild and stable disease. If the message gets across, the market could plausibly double. Actually having titration instructions "on the label" is seen as a positive. There are a comparable number of PV patients sick enough to be considered for Jakafi as MF patients (these docs don't see less-sick PV patients). The price is an obstacle to increased prescribing.